4.5 Article

Somatostatin receptor 5 is palmitoylated by the interacting ZDHHC5 palmitoyltransferase

Journal

FEBS LETTERS
Volume 585, Issue 17, Pages 2665-2670

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.febslet.2011.07.028

Keywords

DHHC; Biotin exchange chemistry; siRNA; TIRF microscopy; Ras Recruitment System; Protein-protein interaction screening

Funding

  1. University of Kuopio
  2. Saastamoinen Foundation
  3. Finnish Cultural Foundation
  4. Deutsche Forschungsgemeinschaft [FOR885, GRK1459]
  5. caesar

Ask authors/readers for more resources

Many G-protein coupled receptors are palmitoylated in their C-terminal, intracellular regions. So far no enzymes responsible for this modification have been described. We identified an interaction of the membrane proximal helix 8 of somatostatin receptor 5 (SSTR5) with the N-terminal region of the putative palmitoyltransferase ZDHHC5 using the Ras recruitment interaction screening system. ZDHHC5 and SSTR5 are colocalized at the plasma membrane and can be efficiently coimmunoprecipitated from transfected cells. Coexpression of ZDHHC5 in HEK293 cells increased palmitoylation of SSTR5 whereas knock-down of endogenous ZDHHC5 by siRNAs decreased it. Our data identify the first palmitoyltransferase for a G-protein coupled receptor. Structured summary of protein interactions: SSTR5 physically interacts with ZDHHC5 by ras recruitment system (View interaction) SSTR5 and ZDHHC5 colocalize by fluorescence microscopy (View interaction) SSTR5 physically interacts with ZDHHC5 by pull down (View interaction) (C) 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biology

Autism-associated SHANK3 missense point mutations impact conformational fluctuations and protein turnover at synapses

Michael Bucher, Stephan Niebling, Yuhao Han, Dmitry Molodenskiy, Fatemeh Hassani Nia, Hans-Juergen Kreienkamp, Dmitri Svergun, Eunjoon Kim, Alla S. Kostyukova, Michael R. Kreutz, Marina Mikhaylova

Summary: Members of the SH3 and ankyrin repeat (SHANK) protein family are considered key scaffolds at glutamatergic synapses, with missense mutations in the canonical SHANK3 isoform potentially linked to ASD. This study demonstrates that ASD-associated point mutations in SHANK3 lead to changes in protein structure, resulting in altered synaptic targeting and protein turnover at synaptic sites in rat primary hippocampal neurons.

ELIFE (2021)

Article Genetics & Heredity

Variant-specific effects define the phenotypic spectrum of HNRNPH2-associated neurodevelopmental disorders in males

Hans-Juergen Kreienkamp, Matias Wagner, Heike Weigand, Allyn McConkie-Rossell, Marie McDonald, Boris Keren, Cyril Mignot, Julie Gauthier, Jean-Francois Soucy, Jacques L. Michaud, Meghan Dumas, Rosemarie Smith, Ulrike Loebel, Maja Hempel, Christian Kubisch, Jonas Denecke, Philippe M. Campeau, Jennifer M. Bain, Davor Lessel

Summary: The study identified male individuals with pathogenic or likely pathogenic variants in the HNRNPH2 gene, some showing mild developmental delay and autistic features, while others had severe neurodevelopmental delay and seizures. Functional analysis and RNA sequencing revealed the impact of the variants on protein function and gene expression.

HUMAN GENETICS (2022)

Article Clinical Neurology

Serum total TDP-43 levels are decreased in frontotemporal dementia patients with C9orf72 repeat expansion or concomitant motoneuron disease phenotype

Kasper Katisko, Nadine Huber, Tarja Kokkola, Paivi Hartikainen, Johanna Kruger, Anna-Leena Heikkinen, Veera Paananen, Ville Leinonen, Ville E. Korhonen, Seppo Helisalmi, Sanna-Kaisa Herukka, Valentina Cantoni, Yasmine Gadola, Silvana Archetti, Anne M. Remes, Annakaisa Haapasalo, Barbara Borroni, Eino Solje

Summary: This study found that total levels of TDP-43 in the serum are decreased in patients with frontotemporal dementia (FTD), especially in those with C9orf72 repeat expansion or concomitant motoneuron disease (FTD-MND) phenotype. Serum-based measurement of TDP-43 may serve as a useful tool for predicting TDP-43 neuropathology associated with C9orf72 repeat expansion and FTD-MND in future diagnostics and intervention studies.

ALZHEIMERS RESEARCH & THERAPY (2022)

Article Neurosciences

Concordance of Alzheimer's Disease-Related Biomarkers Between Intraventricular and Lumbar Cerebrospinal Fluid in Idiopathic Normal Pressure Hydrocephalus

Heikki Lukkarinen, Aleksi Vanninen, Ina Tesseur, Darrel Pemberton, Peter Van der Ark, Tarja Kokkola, Sanna-Kaisa Herukka, Tuomas Rauramaa, Mikko Hiltunen, Kaj Blennow, Henrik Zetterberg, Ville Leinonen

Summary: There is a concentration gradient of Alzheimer's disease cerebrospinal fluid (CSF) biomarkers, including amyloid-beta 1-42 (A beta(42)), total tau (T-tau), and phosphorylated tau 181 (P-tau(181)), between intraventricular (V-CSF) and lumbar CSF (L-CSF) in iNPH patients. The study provides conversion factors between V-CSF and L-CSF, which can be used for diagnostic and prognostic purposes. Linear correlations were found between V-CSF and L-CSF concentrations, both pre- and post-operatively. The equations presented in this study offer a novel tool for clinical use when L-CSF samples are not available or when less invasive shunt reservoir samples are interpreted.

JOURNAL OF ALZHEIMERS DISEASE (2023)

Article Biochemistry & Molecular Biology

Structural deficits in key domains of Shank2 lead to alterations in postsynaptic nanoclusters and to a neurodevelopmental disorder in humans

Fatemeh Hassani Nia, Daniel Woike, Isabel Bento, Stephan Niebling, Debora Tibbe, Kristina Schulz, Daniela Hirnet, Matilda Skiba, Hans-Hinrich Hoenck, Katharina Veith, Christian Guenther, Tasja Scholz, Tatjana Bierhals, Joenna Driemeyer, Renee Bend, Antonio Virgilio Failla, Christian Lohr, Maria Garcia Alai, Hans-Juergen Kreienkamp

Summary: This study investigates the impact of two mutations in the SHANK2 gene on neurodevelopment. The results show that these mutations disrupt the interactions of Shank2 with other proteins, leading to abnormal assembly of postsynaptic protein complexes into nanoclusters. This interference affects the positioning of neurons and synaptic transmission, ultimately impacting normal brain development in humans.

MOLECULAR PSYCHIATRY (2022)

Article Biotechnology & Applied Microbiology

Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models

Rosa Lundbye Allesoe, Agnete Troen Lundgaard, Ricardo Hernandez Medina, Alejandro Aguayo-Orozco, Joachim Johansen, Jakob Nybo Nissen, Caroline Brorsson, Gianluca Mazzoni, Lili Niu, Jorge Hernansanz Biel, Valentas Brasas, Henry Webel, Michael Eriksen Benros, Anders Gorm Pedersen, Piotr Jaroslaw Chmura, Ulrik Plesner Jacobsen, Andrea Mari, Robert Koivula, Anubha Mahajan, Ana Vinuela, Juan Fernandez Tajes, Sapna Sharma, Mark Haid, Mun-Gwan Hong, Petra B. Musholt, Federico De Masi, Josef Vogt, Helle Krogh Pedersen, Valborg Gudmundsdottir, Angus Jones, Gwen Kennedy, Jimmy Bell, E. Louise Thomas, Gary Frost, Henrik Thomsen, Elizaveta Hansen, Tue Haldor Hansen, Henrik Vestergaard, Mirthe Muilwijk, Marieke T. Blom, Leen M. T. Hart, Francois Pattou, Violeta Raverdy, Soren Brage, Tarja Kokkola, Alison Heggie, Donna McEvoy, Miranda Mourby, Jane Kaye, Andrew Hattersley, Timothy McDonald, Martin Ridderstrale, Mark Walker, Ian Forgie, Giuseppe N. Giordano, Imre Pavo, Hartmut Ruetten, Oluf Pedersen, Torben Hansen, Emmanouil Dermitzakis, Paul W. Franks, Jochen M. Schwenk, Jerzy Adamski, Mark McCarthy, Ewan Pearson, Karina Banasik, Simon Rasmussen, Soren Brunak

Summary: The application of multiple omics technologies in biomedical cohorts can reveal patient-level disease characteristics and individualized response to treatment. We developed a deep-learning-based framework, MOVE, to integrate and analyze multi-omics data from a cohort of newly diagnosed type 2 diabetes patients. By using in silico perturbations, we identified drug-omics associations in the multi-modal datasets with higher sensitivity than univariate statistical tests.

NATURE BIOTECHNOLOGY (2023)

Article Neurosciences

Serum Cathepsin S Levels Do Not Show Alterations in Different Clinical, Neuropathological, or Genetic Subtypes of Frontotemporal Dementia Patients nor in Comparison to Healthy Control Individuals

Sami Heikkinen, Nadine Huber, Kasper Katisko, Tarja Kokkola, Paivi Hartikainen, Johanna Kruger, Ville Leinonen, Ville E. Korhonen, Sanna-Kaisa Herukka, Anne M. Remes, Barbara Borroni, Antonella Alberici, Ilenia Libri, Eino Solje, Annakaisa Haapasalo

Summary: Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder with diverse clinical phenotypes and genetic causes. This study aimed to investigate the association between serum cathepsin S levels, a lysosomal and immune function-related enzyme, and specific FTD subgroups. However, no significant alterations were found, suggesting the need for further research on alternative lysosomal proteins as potential biomarkers for FTD.

JOURNAL OF ALZHEIMERS DISEASE (2023)

Article Neurosciences

Cerebrospinal Fluid Diagnostics of Alzheimer's Disease in Patients with Idiopathic Normal Pressure Hydrocephalus

Aleksi Vanninen, Heikki Lukkarinen, Tarja Kokkola, Anne M. Koivisto, Merja Kokki, Tadeusz Musialowicz, Mikko Hiltunen, Henrik Zetterberg, Ville Leinonen, Sanna-Kaisa Herukka, Tuomas Rauramaa

Summary: Alzheimer's disease (AD) is a common cause of dementia, particularly in patients with idiopathic normal pressure hydrocephalus (iNPH). The presence of AD pathology in iNPH is associated with worse outcomes after a shunt procedure. Preoperative diagnosis of AD in iNPH patients is challenging due to reduced cerebrospinal fluid (CSF) AD biomarker concentrations. Our study aimed to determine the effect of iNPH on CSF levels of AD biomarkers and investigate the potential for correction to improve diagnostic value. Results showed significant differences in biomarker levels between groups, and correction for iNPH did not improve diagnostic effectiveness. However, the P-Tau(181)/A beta(1-42) ratio showed some utility in diagnosing AD in iNPH patients.

JOURNAL OF ALZHEIMERS DISEASE (2023)

Correction Biotechnology & Applied Microbiology

Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models (vol 41, pg 399, 2023)

Rosa Lundbye Allesoe, Agnete Troen Lundgaard, Ricardo Hernandez Medina, Alejandro Aguayo-Orozco, Joachim Johansen, Jakob Nybo Nissen, Caroline Brorsson, Gianluca Mazzoni, Lili Niu, Jorge Hernansanz Biel, Cristina Leal Rodriguez, Valentas Brasas, Henry Webel, Michael Eriksen Benros, Anders Gorm Pedersen, Piotr Jaroslaw Chmura, Ulrik Plesner Jacobsen, Andrea Mari, Robert Koivula, Anubha Mahajan, Ana Vinuela, Juan Fernandez Tajes, Sapna Sharma, Mark Haid, Mun-Gwan B. Hong, Petra Musholt, Federico De Masi, Josef Vogt, Helle Krogh Pedersen, Valborg Gudmundsdottir, Angus Jones, Gwen Kennedy, Jimmy Bell, E. Louise Thomas, Gary Frost, Henrik Thomsen, Elizaveta Hansen, Tue Haldor Hansen, Henrik Vestergaard, Mirthe T. Muilwijk, Marieke M. Blom, Leen 't Hart, Francois Pattou, Violeta Raverdy, Soren Brage, Tarja Kokkola, Alison Heggie, Donna McEvoy, Miranda Mourby, Jane Kaye, Andrew Hattersley, Timothy McDonald, Martin Ridderstrale, Mark Walker, Ian N. Forgie, Giuseppe Giordano, Imre Pavo, Hartmut Ruetten, Oluf Pedersen, Torben Hansen, Emmanouil W. Dermitzakis, Paul M. Franks, Jochen Schwenk, Jerzy I. Adamski, Mark McCarthy, Ewan Pearson, Karina Banasik, Simon Rasmussen, Soren Brunak

NATURE BIOTECHNOLOGY (2023)

Article Neurosciences

Protective Alzheimer's disease-associated APP A673T variant predominantly decreases sAPPβ levels in cerebrospinal fluid and 2D/3D cell culture models

Rebekka Wittrahm, Mari Takalo, Teemu Kuulasmaa, Petra M. Maekinen, Petri Maekinen, Sasa Koncarevic, Vadim Fartzdinov, Stefan Selzer, Tarja Kokkola, Leila Antikainen, Henna Martiskainen, Susanna Kemppainen, Mikael Marttinen, Heli Jeskanen, Hannah Rostalski, Eija Rahunen, Miia Kivipelto, Tiia Ngandu, Teemu Natunen, Jean-Charles Lambert, Rudolph E. Tanzi, Doo Yeon Kim, Tuomas Rauramaa, Sanna-Kaisa Herukka, Hilkka Soininen, Markku Laakso, Ian Pike, Ville Leinonen, Annakaisa Haapasalo, Mikko Hiltunen

Summary: The rare A673T variant in the amyloid precursor protein (APP) gene provides protection against Alzheimer's disease (AD). Carriers of the variant exhibit lower levels of amyloid beta (A beta) and better cognitive performance at high age. This study analyzed CSF and plasma samples from APP A673T carriers and control individuals, revealing differentially regulated targets and demonstrating the protective effects of the variant against AD-related alterations.

NEUROBIOLOGY OF DISEASE (2023)

Article Neurosciences

Novel cerebrospinal fluid biomarkers correlating with shunt responsiveness in patients with idiopathic normal pressure hydrocephalus

Sophia Weiner, Antti Junkkari, Mathias Sauer, Antti Luikku, Tuomas Rauramaa, Tarja Kokkola, Sanna-Kaisa Herukka, Kaj Blennow, Henrik Zetterberg, Ville Leinonen, Johan Gobom

Summary: Through proteomic analysis, we identified several potential biomarkers in the cerebrospinal fluid (CSF) that could predict the responsiveness of iNPH patients to shunt surgery. These biomarkers include FABP3, ANXA4, MIF, B3GAT2, ITGB1, YWHAG, OLFM2, TGFBI, and DSG2.

FLUIDS AND BARRIERS OF THE CNS (2023)

Article Multidisciplinary Sciences

A FinnGen pilot clinical recall study for Alzheimer's disease

Valtteri Julkunen, Claudia Schwarz, Juho Kalapudas, Merja Hallikainen, Aino-Kaisa Piironen, Arto Mannermaa, Hanna Kujala, Timo Laitinen, Veli-Matti Kosma, Teemu Paajanen, Reetta Kalviainen, Mikko Hiltunen, Sanna-Kaisa Herukka, Sari Karkkainen, Tarja Kokkola, Mia Urjansson, FinnGen, Markus Perola, Aarno Palotie, Eero Vuoksimaa, Heiko Runz

Summary: In order to develop novel therapies, clinical trials need to be conducted in patient cohorts with high benefit-to-risk ratio. Population-based biobanks with comprehensive health and genetic data hold promise for identifying trial participants, particularly for diseases like Alzheimer's where early intervention is crucial. This study demonstrates the feasibility of recalling FinnGen participants for a clinical study, successfully obtaining customized clinical data and validating registry entries.

SCIENTIFIC REPORTS (2023)

Article Endocrinology & Metabolism

Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials

Adem Y. Dawed, Andrea Mari, Andrew Brown, Timothy J. McDonald, Lin Li, Shuaicheng Wang, Mun-Gwan Hong, Sapna Sharma, Neil R. Robertson, Anubha Mahajan, Xuan Wang, Mark Walker, Stephen Gough, Leen M. 't Hart, Kaixin Zhou, Ian Forgie, Hartmut Ruetten, Imre Pavo, Pallav Bhatnagar, Angus G. Jones, Ewan R. Pearson, for the D. I. R. E. C. T. consortium DIRECT consortium

Summary: This study identified genetic variants associated with the response to GLP-1 receptor agonist treatment in patients with type 2 diabetes, which provides valuable insights for clinical decision making and personalized medicine.

LANCET DIABETES & ENDOCRINOLOGY (2023)

Article Multidisciplinary Sciences

Mutations affecting the N-terminal domains of SHANK3 point to different pathomechanisms in neurodevelopmental disorders

Daniel Woike, Emily Wang, Debora Tibbe, Fatemeh Hassani Nia, Antonio Virgilio Failla, Maria Kibaek, Tinett Martesen Overgard, Martin J. Larsen, Christina R. Fagerberg, Igor Barsukov, Hans-Juegen Kreienkamp

Summary: Shank proteins are important for the structure of excitatory synapses. Mutations in SHANK genes are linked to autism and intellectual disability. This study identifies a new missense mutation in SHANK3 that is associated with an ADHD-like phenotype. Functional analysis shows that these mutations disrupt the interactions between Shank3 and other key molecules, leading to severe neurodevelopmental pathology.

SCIENTIFIC REPORTS (2022)

Article Cell Biology

Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study

Agata Wesolowska-Andersen, Caroline A. Brorsson, Roberto Bizzotto, Andrea Mari, Andrea Tura, Robert Koivula, Anubha Mahajan, Ana Vinuela, Juan Fernandez Tajes, Sapna Sharma, Mark Haid, Cornelia Prehn, Anna Artati, Mun-Gwan Hong, Petra B. Musholt, Azra Kurbasic, Federico De Masi, Kostas Tsirigos, Helle Krogh Pedersen, Valborg Gudmundsdottir, Cecilia Engel Thomas, Karina Banasik, Chrisopher Jennison, Angus Jones, Gwen Kennedy, Jimmy Bell, Louise Thomas, Gary Frost, Henrik Thomsen, Kristine Allin, Tue Haldor Hansen, Henrik Vestergaard, Torben Hansen, Femke Rutters, Petra Elders, Leen T'Hart, Amelie Bonnefond, Mickael Canouil, Soren Brage, Tarja Kokkola, Alison Heggie, Donna McEvoy, Andrew Hattersley, Timothy McDonald, Harriet Teare, Martin Ridderstrale, Mark Walker, Ian Forgie, Giuseppe N. Giordano, Philippe Froguel, Imre Pavo, Hartmut Ruetten, Oluf Pedersen, Emmanouil Dermitzakis, Paul W. Franks, Jochen M. Schwenk, Jerzy Adamski, Ewan Pearson, Mark McCarthy, Soren Brunak

Summary: This study classified newly diagnosed T2D patients into different subgroups based on their disease patterns and associated biomarkers, demonstrating that the clinical heterogeneity of T2D can be mapped to heterogeneity in individual etiological processes, providing potential for personalized treatments.

CELL REPORTS MEDICINE (2022)

No Data Available